INTRODUCTION {#s1}
============

Diabetes mellitus (DM) is a major cause of morbidity and mortality worldwide and has resulted in deaths of approximately five million people aged between 20 and 79 years in 2015 according to the International diabetes federation \[[@R1]\]. Sub-Saharan Africa (SSA) is currently experiencing the fastest relative growth of people with diabetes that remains undiagnosed in many \[[@R2]\]. In 2015, the International Diabetes Federation (IDF) Diabetes Atlas, estimated that nearly 2/3^rd^ of the 14.2 million sub-Saharan Africans adults with diabetes were undiagnosed \[[@R1]\]. Overt DM is often preceded by prediabetes, a term used to define subjects with either or both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Approximately, 5--10% of individuals with prediabetes develop diabetes annually with up to 70% eventually progressing to the stage of the disease \[[@R3], [@R4]\]. Lifestyle modifications or drug interventions can delay the onset of DM \[[@R5], [@R6]\], however this is dependent on the identification of those at risk of progression to overt DM. This identification is heavily dependent on the diagnostic criteria which are continually revised and vary across stakeholders. For example, the World Health organisation (WHO) and American Diabetes Federation differ in the description of IFG, respectively 6.1 -- 6.9 mmol/\| and 5.6--6.9 mmol/L. Moreover in 2010 the ADA included HbA1c ranging from 5.7% to 6.4% as diagnostic criterion for prediabetes. These realities validate the critical need for earlier and more efficient biomarkers for diabetes risk screening. In this regard, recent studies \[[@R7]--[@R9]\] have shown that micro RNAs (miRNAs) are useful as early markers of certain disease types, including diabetes.

To date, over 1881 miRNA precursors that can generate over 2588 mature miRNAs have been identified in the human genome ([www.mirbase.org](http://www.mirbase.org/)) which control ∼50% of all mammalian protein-coding genes \[[@R10]\]. miRNAs are a class of small (∼19--24 nucleotides in length), endogenous, evolutionarily conserved RNAs that function as posttranscriptional regulators of gene expression \[[@R11]--[@R13]\]. They primarily function by binding to complementary target sequences in messenger RNA (mRNA) and by interfering with the translational machinery, thereby prevent or alter the production of the protein product \[[@R11]--[@R13]\]. In addition to repressing translation, miRNA binding to its target mRNA also triggers the recruitment and association of mRNA decay factors, leading to mRNA destabilization, degradation, and resultant decrease in expression levels \[[@R13]\]. Dysregulated expression of miRNAs is associated with the pathogenesis of a variety of diseases including dysglycaemia and vascular complications. Several miRNAs that are involved in the regulation of insulin signaling, lipid and glucose homeostasis have been identified in various tissues \[[@R14], [@R15]\], however, findings are inconsistent owing to techniques, sample and genetic diversity of populations studied \[[@R16], [@R17]\].

Despite the growing evidence of the important role and potential diagnostic value of miRNAs in dysglycaemia, such properties are yet to be demonstrated in the African setting. Therefore, in the present study we aimed to identify dysregulated miRNA in a South African mixed ancestry population previously reported to be at high risk of diabetes \[[@R18]\]. To avoid potential bias from treatment induced alterations in miRNA expression, we focused on individuals with normal glucose tolerance (NGT), prediabetes individuals with IGT only and those with screen-detected diabetes who had not initiated glucose lowering drug treatment.

RESULTS {#s2}
=======

General characteristics of participants {#s2_1}
---------------------------------------

The characteristics of participants overall, and according to glucose tolerance status are summarised in Table [1](#T1){ref-type="table"}. All participants were female and the mean levels of diastolic blood pressure, systolic blood pressure, low density lipoprotein cholesterol, high density lipoprotein cholesterol, age, body mass index, and serum cotinine did not differ significantly by status for glucose tolerance (all p≥0.06).

###### Characteristics of the 36 women included overall, and by status for glucose tolerance

  Characteristics                       Total                 Normal                IGT                     New DM                p-value
  ------------------------------------- --------------------- --------------------- ----------------------- --------------------- -----------
  n                                     36                    12                    12                      12                    
  Age (years)                           53.4 (7.8)            52.1 (7.8)            53.5 (8.5)              54.8 (7.5)            0.717
  Weight (kg)                           76.8 (19.7)           70.2 (18.9)           79.3 (21.7)             80.8 (18.3)           0.370
  Height (cm)                           155.8 (6.5)           157.2 (7.9)           154.4 (6.0)             156.1 (5.9)           0.600
  Body mass index (kg/m^2^)             31.5 (8.4)            27.3 (5.8)            33.3 (9.1)              33.5 (8.9)            0.141
  Waist circumference (cm)              93.9 (18.7)           83.2 (18.5)           97.1 (13.8)             101.3 (19.7)          0.041
  Hip circumference (cm)                107.1 (17.7)          102.0 (18.4)          109.9 (18.6)            109.4 (16.6)          0.487
  Waist/hip ratio                       0.87 (0.08)           0.81 (0.07)           0.89 (0.06)             0.92 (0.07)           0.001
  Systolic blood pressure (mmHg)        138.4 (27.5)          135.3 (30.8)          137.0 (18.5)            142.9 (32.9)          0.784
  Diastolic blood pressure (mmHg)       87.0 (18.0)           78.0 (16.1)           88.9 (11.7)             94.2 (22.1)           0.077
  Pulse rate (bpm)                      72.1 (13.5)           64.8 (12.2)           71.3 (5.8)              80.1 (16.4)           0.016
  Fasting plasma glucose (mmol/L)       6.3 (2.9)             4.6 (0.8)             5.3 (0.5)               9.1 (3.6)             \< 0.0001
  2-hour glucose (mmol/L)               10.5 (5.5)            5.3 (1.6)             9.3 (0.9)               16.5 (4.7)            \< 0.0001
  Fasting insulin (mIU/L)^\*^           8.10 (5.70-12.50)     5.65 (2.95-7.85)      9.45 (7.55-12.50)       14.10 (5.90-21.20)    0.0058
  2-hour Insulin (mIU/L)^\*^            53.20 (29.20-97.90)   28.50 (17.80-40.40)   111.20 (60.20-187.20)   48.80 (31.45-83.30)   0.0044
  Triglycerides (mmol/L)                1.6 (1.1)             1.0 (0.3)             1.76 (1.0)              2.2 (1.3)             0.023
  LDL Cholesterol (Measured) (mmol/L)   3.6 (1.0)             3.3 (1.0)             3.5 (1.0)               4.2 (0.8)             0.060
  HDL cholesterol (mmol/L)              1.4 (0.5)             1.6 (0.5)             1.3 (0.4)               1.4 (0.6)             0.451
  Total cholesterol (mmol/L)            5.7 (1.0)             5.5 (1.1)             5.4 (1.0)               6.4 (0.8)             0.043
  Total/HDL cholesterol ratio           4.3 (1.4)             3.7 (1.2)             4.3 (1.3)               5.02 (1.4)            0.077
  High-sensitivity CRP (mg/L)           7.84 (8.56)           3.12 (2.73)           9.28 (5.93)             11.11 (12.34)         0.052
  Cotinine (ng/mL)^\*^                  22.5 (10.0-220.5)     22.5 (10.0-261.0)     91.0 (10.0-220.0)       85.0 (10.0-206.0)     1.0000

^\*^, median \[25^th^-75^th^ percentiles), and p-values from Kruskal wallis test.

miRNA expression profiling {#s2_2}
--------------------------

All 36 samples (12 NGT, 12 IGT and 12 screen-detected diabetes) met the quality control standards. The clean reads (Adapter-trimmed reads) met and exceeded the specified sequencing coverage of 5 M ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). We generated Heat Map and Unsupervised Hierarchical Clustering on all expressed miRNAs (at least expressed in one sample) to produce miRNA or condition trees to allow us to pick out groups of similar miRNA. The result of hierarchical clustering on conditions showed a distinguishable miRNA expression profile among samples (Figure [1](#F1){ref-type="fig"}). For the identification of differentially expressed miRNAs, we computed "fold change" (i.e. the ratio of the group averages) and p-value between each group. miRNAs having fold changes ≥1.3, p-value ≤0.1 were selected as the differentially expressed miRNAs. Based on pre-specified criteria, we then used volcano plots to visualize the significantly differentially expressed pre-miRNAs between the study groups (Figure [2](#F2){ref-type="fig"}). In total, we identified a total of 261 significant pre-miRNAs that generated 237 mature miRNAs at varying levels of expression. Upregulated pre-miRNA (mature miRNA) were 117 (107) between screen-detected DM versus NGT, 58 (54) between IGT and NGT and 56 (50) between screen-detected DM and IGT, and downregulated miRNAs were respectively, 3 (2); 9 (7) and 18 (17). Fifty seven (22%) of the differentially expressed miRNAs were novel, of which 21 were upregulated in DM versus NGT, 19 in IGT versus NGT and 8 in DM versus IGT, whilst none were downregulated in DM versus NGT, 1 in IGT versus NGT and 8 in DM versus IGT. The details of the ten most differentially expressed miRNAs can be found in [Supplementary Table 2](#SD2){ref-type="supplementary-material"} which shows that miR-15b-5p remained amongst the ten most differentially expressed miRNA when screen-detected diabetes was compared to either NGT or IGT. Among the down-regulated species, miR-486-5p was found in both screen-detected DM versus NGT and screen-detected DM versus IGT. A total of 28 pre-miRNA encoding 25 matured miRNAs were upregulated in both screen-detected DM and IGT when compared to NGT (Table [2](#T2){ref-type="table"}). Among the ten most differentially expressed miRNAs in IGT versus NGT, eight (miR-99b-5p, -30e-3p, -1260a, -4443, -novel-chr2_50989, -1260b, -151a-5p, -miR-223-3) were also dysregulated in screen-detected DM when compared to NGT. Two of these, miR-novel-chr2_50989 and miR-223-3p were also found to be amongst the top ten differentially expressed miRNAs between screen-detected DM versus NGT.

###### Differential miRNA expression in glucose tolerance groups

The heatmap shows all differentially expressed miRNAs at adjusted p-value \< 0.05. A. IGT versus NGT; B. screen-detected diabetes versus NGT; C. IGT versus screen-detected diabetes. Signal intensity was expressed as the log2 ratio between groups. Samples were grouped using hierarchical clustering based on similar expression profiles. Red, under-expression, white, no change, blue, overexpression.
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![Volcano plots of precursor miRNA in individuals with screen-detected diabetes (DM), impaired glucose tolerance (IGT) compared to those with normal glucose tolerance (NGT)\
Differentially expressed miRNAs are those having fold changes ≥1.3, p-value ≤0.1.](oncotarget-09-30485-g002){#F2}

###### Dysregulated Pre miRNA and mature miRNA in screen-detected diabetes and impaired glucose tolerance versus normoglucotolerant individuals

  Pre-miRNA accession number   Pre-miRNA                   miRNA accession number      miRNA                       DM vs NGT fold change   p-value       IGT vs NGT fold change   p-value
  ---------------------------- --------------------------- --------------------------- --------------------------- ----------------------- ------------- ------------------------ -------------
  MI0000746                    hsa-mir-99b                 MIMAT0000689                hsa-miR-99b-5p              1,820588                0,000138758   2,959804                 0,082063563
  MI0000749                    hsa-mir-30e                 MIMAT0000693                hsa-miR-30e-3p              1,784615                0,007252301   2,398601                 0,007101456
  MYNO2438                     hsa-mir-novel-chr2_50989    hsa-miR-novel-chr2_50989    hsa-miR-novel-chr2_50989    2,355212                1,37684E-06   2.0                      0,064120232
  MI0006394                    hsa-mir-1260a               MIMAT0005911                hsa-miR-1260a               1,713994                0,01312321    2,151037                 0,011997711
  MI0016786                    hsa-mir-4443                MIMAT0018961                hsa-miR-4443                1,551667                0,085964281   2,115556                 0,027357273
  MI0000300                    hsa-mir-223                 MIMAT0000280                hsa-miR-223-3p              1,920202                0,002582624   1,678788                 0,046035966
  MI0014197                    hsa-mir-1260b               MIMAT0015041                hsa-miR-1260b               1,697833                0,009034611   1,917339                 0,021651005
  MI0000438                    hsa-mir-15b                 MIMAT0000417                hsa-miR-15b-5p              1,885503                1,26022E-05   1,409377                 0,057613054
  MYNO2570                     hsa-mir-novel-chr20_44211   hsa-miR-novel-chr20_44211   hsa-miR-novel-chr20_44211   1,813224                8,42372E-06   1,60939                  0,005237963
  MYNO8                        hsa-mir-novel-chr7_78559    hsa-miR-novel-chr7_78559    hsa-miR-novel-chr7_78559    1,801314                0,013459765   1,535304                 0,062496157
  MI0000809                    hsa-mir-151a                MIMAT0004697                hsa-miR-151a-5p             1,705487                0,042803475   1,723404                 0,075509343
  MI0016746                    hsa-mir-548o-2              MIMAT0005919                hsa-miR-548o-3p             1,657303                0,000348585   1,598315                 0,011517573
  MI0006402                    hsa-mir-548o                MIMAT0005919                hsa-miR-548o-3p             1,657303                0,000348585   1,598315                 0,011517573
  MI0003772                    hsa-mir-151b                MIMAT0010214                hsa-miR-151b                1,397004                0,053368366   1,58427                  0,039862735
  MYNO2414                     hsa-mir-novel-chr1_36178    hsa-miR-novel-chr1_36178    hsa-miR-novel-chr1_36178    1,577617                0,015973544   1,483755                 0,051048972
  MI0001448                    hsa-mir-425                 MIMAT0003393                hsa-miR-425-5p              1,545474                0,007580947   1,366328                 0,0612974
  MYNO2060                     hsa-mir-novel-chr5_70692    hsa-miR-novel-chr5_70692    hsa-miR-novel-chr5_70692    1,524669                0,001574976   1,405218                 0,085501759
  MI0000456                    hsa-mir-140                 MIMAT0004597                hsa-miR-140-3p              1,486817                0,013053757   1,521131                 0,056333534
  MI0000108                    hsa-mir-103a-2              MIMAT0000101                hsa-miR-103a-3p             1,514849                0,001742993   1,445334                 0,06271756
  MI0000109                    hsa-mir-103a-1              MIMAT0000101                hsa-miR-103a-3p             1,514822                0,001750868   1,445326                 0,062651884
  MYNO1801                     hsa-mir-novel-chr17_28671   hsa-miR-novel-chr17_28671   hsa-miR-novel-chr17_28671   1,433333                0,033228045   1,51                     0,029705075
  MI0000289                    hsa-mir-181a-1              MIMAT0000256                hsa-miR-181a-5p             1,465751                0,003192238   1,3978                   0,02734155
  MI0000269                    hsa-mir-181a-2              MIMAT0000256                hsa-miR-181a-5p             1,465751                0,003192238   1,3978                   0,02734155
  MI0016005                    hsa-mir-3615                MIMAT0017994                hsa-miR-3615                1,390032                0,009862178   1,42043                  0,028236924
  MYNO12                       hsa-mir-novel-chr19_33126   hsa-miR-novel-chr19_33126   hsa-miR-novel-chr19_33126   1,410758                0,001410185   1,337408                 0,094043894
  MI0000269                    hsa-mir-181a-2              MIMAT0004558                hsa-miR-181a-2-3p           1,34125                 0,005944189   1,3025                   0,077287593

Quantitative real time PCR of MicroRNAs {#s2_3}
---------------------------------------

As shown in Figure [3](#F3){ref-type="fig"}, we confirmed up-regulation of let7e-5p, let7f-5p, miR-15b-5p, miR-99b-5p, miR-103a-3p in subjects with diabetes. We also confirmed the non-expression of let7e-5p, let7f-5p in individuals with IGT.

![Quantitative real time PCR of differentially expressed miRNAs in individuals with screen-detected diabetes (DM), impaired glucose tolerance (IGT) and normol glucose tolerance (NGT)\
Data presented as mean and range.](oncotarget-09-30485-g003){#F3}

Target prediction and functional enrichment analysis {#s2_4}
----------------------------------------------------

We employed three databases namely, Mirbase, Miranda and Targetscan to conduct the analyses to improve the accuracy of our target site predictions. The target genes identified by the three databases were 690 in the screen-detected DM versus NGT, 535 screen-detected DM versus IGT, and 320 in IGT versus NGT. The predicted target sites of dysregluted miRNAs are shown in the Venn diagrams (Figure [4](#F4){ref-type="fig"}). The KEGG pathway analysis demonstrated 107 pathways ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}). These pathways include those associated with signal transduction, cell-cell communications, cell growth and death, immune response, endocrine system and metabolic diseases.

![Venn diagrams showing target genes with three databases (TargetScan, Miranda and Microcosm v5) in individuals with screen-detected diabetes (DM), impaired glucose tolerance (IGT) compared to those with normal glucose tolerance (NGT)](oncotarget-09-30485-g004){#F4}

DISCUSSION {#s3}
==========

In this study, we employed high throughput sequencing to identify differentially expressed miRNAs associated with IGT and untreated diabetes in whole blood of South African mixed ancestry women, which in an earlier study we had established a high prevalence of undiagnosed IGT and DM \[18). We observed evidence for differential expression of 61 in IGT, 109 in screen-detected diabetes both when compared to individuals with normal glucose tolerance, of which 25 were common in both conditions. Although several of these dysregulated miRNAs have been linked to diabetic and non-diabetic hyperglycaemia, we also uncovered 57 novel miRNAs. Of note is hsa-miR-novel-chr2_50989 which had the highest fold change in screen-detected DM and remained in the top ten differentially expressed miRNAs in IGT. Functional annotation of genes that are potentially regulated by the miRNAs implicated showed that signal transduction pathways (PI3K-Akt, MAPK, HIF-1, cAMP, FoxO, ErbB, Ras, Rap1 and insulin resistance); carbohydrate metabolism; glycan biosynthesis and metabolism, cell communication, cell growth and death; immune system; endocrine system and metabolic diseases are likely involved in the development of hyperglycaemia in this population.

Successful diabetes prevention implementation strategies rely on accurate identification of people with prediabetes, who are likely to progress to the full stage of time. To this end, the diagnosis of IGT for instance, requires individuals to be subjected to the cumbersome oral glucose overload and measurement of blood glucose post 2 hours \[[@R19], [@R20]\]. Consequently, individuals with this category of prediabetes largely remain undiagnosed. However, the emerging evidence for the role of miRNAs in the development of human diseases including diabetes is encouraging. In the development of diabetes, miRNAs have been reported to regulate metabolism, adipocyte differentiation, pancreatic development, β-cell mass, insulin biosynthesis, secretion, and signaling \[[@R21]--[@R25]\], underscoring their important role in the early diagnosis, pathogenesis and treatment of diabetes.

Some of the dysregulated miRNAs found in our study corroborate findings of many other studies that have aimed to characterize miRNAs in different tissue types of individuals with DM and/or prediabetes. A recent systematic study of dysregulated miRNAs in T2DM identified a total of 158 dysregulated miRNAs in adipose, islet, skeletal muscle, whole blood, PBMC, plasma and serum \[[@R26]\]. Similarly we found 36 (23%) of these miRNAs dysregulated in T2DM and IGT ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}). Furthermore, three additional miRNAs (miR-27b, miR-98, and miR-21) previously reported to be dysregulated in mixed ethnic ancestry women with IGT or T2DM \[[@R27]\] were also differentially expressed in screen-detected DM in our sample. The miRNAs found in the current study and others have been shown to play a direct role in insulin production and secretion \[[@R21]-[@R25], [@R28]\]. This was confirmed by bioinformatics techniques we applied to identify the potential biological functions affected by the miRNA signatures. p53 signaling, PI3K/Akt, p53 signaling and MAPK were respectively the 2^nd^, 3^rd^ and 6^th^ targeted significant pathways in enrichment analysis by KEGG. The PI3K/Akt/ and MAPK pathways plays a major signaling role in the cellular response to extracellular stimuli, including glucose homeostasis, cell proliferation and survival \[[@R29]\]. In glucose homeostasis, the activation of these pathways is directly under the control of insulin receptors upon insulin stimulation \[[@R30]\]. A number of miRNAs such as the let-7 family, 30ep-5p \[[@R26], [@R31], [@R32]\] found in this study and others have been shown to be involved in these pathways. These miRNAs have be reported to exert their function by suppressing the expression of insulin receptor genes \[[@R17], [@R32]\].

Although many similarities were found between this study and others, our study is unique for uncovering that some of these miRNAs were differentially expressed between diabetic and non-diabetic dysglycaemia. Indeed, using OGTT to characterise asymptomatic participants, we identified three miRNAs that potentially distinguish between diabetic and non-diabetic hyperglycaemia. For example, miR-126-3p, and miR-28-3p were upregulated in IGT when compared to screen-detected DM, whilst miR-486-5p was down-regulated in screen-detected DM in comparison to either IGT or NGT. miR-126 is expressed by cells that modulate inflammatory response and vascular homeostasis through enhanced production of anti-inflammatory chemokines, and has been shown to be reduced in T2DM \[[@R33]--[@R37]\]. The downgrelation of miR-126 has been shown to be mostly pronounced in poorly controlled T2DM and in T2DM with complications when compared to sujects with T2DM without complication \[[@R38]\]. Similarly, in a study that investigated miR-126 in serum of DM patients with varying degrees of retinopathy, miR-126 was reduced in patients versus the controls, but lowest in patients with proliferative diabetic retinopathy \[[@R39]\]. Taken together, our findings of upregulated miR-126 and others in IGT versus screen-detected DM most probably point towards a cascading reduction with respect to diabetes related complications suggesting a potential role for miR-126 in distinguishing prediabetes from diabetes. Indeed, Liu et al \[[@R40]\]), examined the usefulness of miR-126 in predicting prediabetes and T2DM and reported lower levels in T2DM compared to prediabetes, even though both were significanlty lower than in healthy controls. It is important to note that a number of miRNAs including novel ones with potential to distinguish between hyperglycaemia and normal glucose tolerance were uncovered in the current study. For example, miR- hsa-miR-1299 had the highest fold change in IGT versus controls and was not detected in individuals with DM, whilst mir-novel-chr2_55842 was amongst the 10^th^ most differentially expressed in IGT only. In hepato-hepatocellular carcinoma, miR-1299 inhibits cell proliferation by targeting cyclin-dependent kinase 6, \[[@R41]\] however there is limited information about miR-1299 in diabetes. Therefore, further studies are needed to elucidate the molecular mechanisms of miR-1299 and other novel miRNAs identified in this study.

The major strengths of this study lies in the choice of high throughput sequencing which is a powerful strategy for identifying known and new candidate miRNAs related to the disease process. Furthermore, this method was ideal to cover unidentified miRNAs in this rather heterogeneous mixed ancestry population. Importantly, we did not include individuals on diabetes lowering treatment as this had the potential to bias our findings. Metformin, a drug that targets protein kinase activity and which is widely used for the treatment of insulin resistance, is believed to operate mainly by activating the insulin signaling pathway AMPK \[[@R29]\]. Lastly, our study participants were well-characterized by OGTT, and were matched for age, sex, blood pressure, serum cotinine and cholesterol. Therefore, we were able to uncover several known and novel miRNAs showing statistically significant evidence for differential expression by glucose tolerance status. In total we identified 57 novel differentially expressed miRNAs of which miR-novel-chr2_50989 deserves further consideration as this was amongst the top differentially expressed in both screen-detected and IGT. Despite these strengths, our study has limitations. Although our sample size is comparable to similar studies, we still consider it small. A small sample size has the potential to limit the ability to detect some significant differences in miRNA expression levels. Although, we employed RT-qPCR to confirm the expression of miRNAs identified by the deep sequencing approach, this was not performed in an independent sample. Therefore, a larger independent study is required to confirm our findings in this population. The cross-sectional design of this study limits our ability to draw conclusions with regards to association with disease progression, or to explore the role of particularly novel miRNAS in the molecular mechanisms of hyperglycaemia. Despite these considerations, several miRNAs whose molecular mechanism has been previously investigated were also found in this population group.

Overall, in addition to complementing earlier studies on miRNAs in prediabetes and diabetes, our findings provide evidence of known and novel differentially expressed miRNAs in African mixed ancestry individuals with IGT and screen-detected DM. We further observed that the aberrant expression profiles of miRNAs were linked to several biological processes, such as signal transduction, cell-cell communications, cell growth and death, immune response, endocrine system and metabolic diseases. Larger prospective studies in this and other racial populations from Africa are needed to characterize the molecular mechanisms of African-specific differentially expressed miRNAs, as well as assess their potential to predict worsening of glucose tolerance status.

MATERIALS AND METHODS {#s4}
=====================

Ethical approval of the study {#s4_1}
-----------------------------

This investigation is based on the Cape Town Vascular and Metabolic Health (VMH) study, that has been approved by the Research Ethics Committees of the Cape Peninsula University of Technology (CPUT) and Stellenbosch University (respectively, NHREC: REC - 230 408 -- 014 and N14/01/003). For this sub-study, ethical approval was also obtained from the CPUT Health and Wellness Sciences Research Ethics Committee (CPUT/HW-REC 2014/H08). The study was conducted according to the Code of Ethics of the World Medical Association (Declaration of Helsinki). All participants signed written informed consent after all the procedures had been fully explained in the language of their choice.

Study design and procedures {#s4_2}
---------------------------

This was a cross-sectional study involving participants from the ongoing Cape Town Vascular and Metabolic Health (VMH) study. VMH is an extension of the Cape Town Bellville South study, which has been described in details previously \[[@R42], [@R43]\]. Data collection was based on a standardised questionnaire available in the electronic form on a password-protected personal digital assistant (PDA). Upon completion of the assessment of each participant, data were automatically encrypted and transmitted via mobile internet connection to a dedicated server, from which they were checked for completion, downloaded and stored for future use. Physical examination involved data collection on blood pressure (BP) which was measured according to the World Health Organisation (WHO) guidelines \[[@R44]\], using a semi-automatic digital blood pressure monitor (Omron M6 comfort-preformed cuff BP Monitor) on the right arm in sitting position and at rest for at least 10 minutes. Body weight (to the nearest 0.1 kg) was measured with the subject in light clothing and without shoes, using an Omron body fat meter HBF-511digital bathroom scale, which was calibrated and standardized using a weight of known mass. Height to the nearest centimetre was measured with a stadiometer, with subjects standing on a flat surface. Body Mass Index (BMI) was calculated as weight per square meter (kg/m^2^). Waist circumference was measured with a non-elastic tape at the level of the narrowest part of the torso, as seen from the anterior view. BP and anthropometric measurements were performed three times and their average used for analysis.

All participants underwent a 75 g oral glucose tolerance test (OGTT) as recommended by the WHO \[[@R20]\]. Further, the following biochemical parameters were analyzed at an ISO 15189 accredited Pathology practice (PathCare, Reference Laboratory, Cape Town, South Africa): glycated haemoglobin (HbA1c) by High Perfomance Liquid Chromotography (Biorad Variant Turbo, BioRad, South Africa); serum insulin by a paramagnetic particle chemiluminescence assay (Beckman DXI, Beckman Coulter, South Africa); serum cotinine by Competitive Chemiluminescent (Immulite 2000, Siemens, South Africa); plasma glucose by enzymatic hexokinase method (Beckman AU, Beckman Coulter, South Africa); total cholesterol (TC); high density lipoprotein cholesterol (HDL-c) by enzymatic immunoinhibition -- End Point (Beckman AU, Beckman Coulter, South Africa);; triglycerides (TG) by glycerol phosphate oxidase-peroxidase, End Point (Beckman AU, Beckman Coulter, South Africa); low density lipoprotein cholesterol (LDL) by enzymatic selective protection -- End Point (Beckman AU, Beckman Coulter, South Africa); and ultrasensitive C-reactive protein (CRP) by Latex Particle immunoturbidimetry (Beckman AU, Beckman Coulter, South Africa). In addition, blood sample were collected in a Tempus RNA tube (Applied Biosystems) and stored at -80 degrees for RNA extraction and analysis. Participants selected for this analysis were 12 individuals with screen-detected diabetes, 12 with prediabetes and 12 with normal glucose tolerance, matched for age, blood pressure, smoking and body mass index.

RNA isolation {#s4_3}
-------------

Total RNA, including miRNA, was isolated from whole blood using MagMax total RNA isolation kit (ThermoFisher Scientific, South Africa) according to manufacture's instructions. The concentration and purity of the RNA samples were determined using a NanoDrop ND-1000 spectrophotometer and RNA samples that met a 260/280 value \>1.8 and a concentration \> 20ug/ul were used for miRNA sequencing. Furthermore, RNA integrity was evaluated by denaturing agarose gel electrophoresis.

miRNA sequencing {#s4_4}
----------------

Small RNA library construction, deep sequencing, and data processing were performed at Arraystar Inc., Rockville, USA. Total RNA of each sample was used to prepare the miRNA sequencing library which included the following steps: 1) 3\'-adapter ligation with T4 RNA ligase 2 (truncated); 2) 5\'-adapter ligation with T4 RNA ligase; 3) cDNA synthesis with RT primer; 4) PCR amplification; 5) extraction and purification of ∼130-150 bp PCR amplified fragments (correspond to ∼15-35 nt small RNAs) from the PAGE gel. After the completed libraries were quantified with Agilent 2100 Bioanalyzer, the DNA fragments in the libraries were denatured with 0.1M NaOH to generate single-stranded DNA molecules, captured on Illumina flow cells, amplified *in situ* and finally sequenced for 51 cycles on Illumina HiSeq according to the manufacturer's instruction. Raw sequences were generated as clean reads from Illumina HiSeq by real-time base calling and quality filtering. The clean reads that passed the quality filter were processed to remove the adaptor sequence as the trimmed reads. The trimmed reads (length ≥ 15 nt) were aligned to the human pre-miRNA in miRBase 21, using novoalign software. The miRNA expression levels were measured and normalized as transcripts per million of total aligned miRNA reads (TPM). miRNAs having fold changes \>= 1.3, P-value \<= 0.1 were selected as the differentially expressed miRNAs. Novel miRNAs were predicted by algorithms such as miRDeep \[[@R45]\].

Analysis of individual miRNAs using quantitative reverse-transcription PCR (RT-qPCR) {#s4_5}
------------------------------------------------------------------------------------

To confirm the expression of miRNAs identified by the deep sequencing approach, RT-qPCR analysis was performed using miRNA from the same samples used in miRNA deep sequencing. miRNA was converted to cDNA using the TaqMan MicroRNA Reverse Transcription Kit according to the manufacturer\'s protocol (Life Technologies, USA). miRNA expression levels were assessed using and TaqMan miRNA Assay primers in conjuction with Quantum Studio 7 (Life Technologies, USA). The delta delta Ct (2^−ΔΔCT^) method was used to determine fold-change of miRNA expression between samples using the average expression of RNU6B, and miR-425 as endogenous controls. We selected the following miRNA for validation, let7e-5p, let7f-5p, miR-15b-5p, miR-99b-5p, miR-103a-3p.

Target prediction and functional enrichment analysis {#s4_6}
----------------------------------------------------

To improve the accuracy of messenger RNA (mRNA) gene targets, we used three different prediction algorithms, TargetScan (v6.2) (<http://www.targetscan.org/vert_60/>), Miranda, and Microcosm v5. The Venny tool (Venny v2.0.2) ([http://bioinfogp.cnb.csic.es](http://bioinfogp.cnb.csic.es/)) was used to filter miRNA gene targets common to all three programs. miRNAs with the highest fold changes among the increased and decreased miRNAs were chosen for mRNA network analysis. These networks showed how one miRNA targets several mRNAs, which in turn can be targeted by several miRNAs and these are shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. Commonly predicted gene targets were subjected to functional analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG). We used a conservative Fisher's exact test and the false discovery rate method to calculate the targeted pathways.

Statistical analysis {#s4_7}
--------------------

Data were analysed using the R statistical software version 3.2.2 \[2015-08-14\], (The R Foundation for Statistical Computing, Vienna, Austria). Variables are summarized as mean and standard deviation or median \[25^th^-75^th^ percentiles). The Shapiro-Wilk W test was employed to determine whether the data were normally distributed, based on probability thresholds of p\>0.1.
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